This Article Full Text Full Text (PDF) All Versions of this Article: 51/2/528    most recent HYPERTENSIONAHA.107.101634v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Tsukuda, K. Articles by Horiuchi, M. Search for Related Content PubMed PubMed Citation Articles by Tsukuda, K. Articles by Horiuchi, M. Related Collections Behavioral/psychosocial - treatment Animal models of human disease Type 2 diabetes

(Hypertension. 2008;51:528.)
© 2008 American Heart Association, Inc.

Original Articles Part 2

Diabetes-Associated Cognitive Impairment Is Improved by a Calcium Channel Blocker, Nifedipine

Kana Tsukuda; Masaki Mogi; Jian-Mei Li; Jun Iwanami; Li-Juan Min; Akiko Sakata; Teppei Fujita; Masaru Iwai; Masatsugu Horiuchi

From the Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University, Graduate School of Medicine, Ehime, Japan.

Correspondence to Masatsugu Horiuchi, Department of Molecular Cardiovascular Biology and Pharmacology, Ehime University, Graduate School of Medicine, Shitsukawa, Tohon, Ehime 791-0295, Japan. E-mail horiuchi{at}m.ehime-u.ac.jp

Nifedipine, a calcium channel blocker, has been reported to exert pleiotropic effects on atherosclerosis, mainly through its antioxidative properties. However, the effect of the calcium channel blocker on cognitive impairment associated with type 2 diabetes mellitus is not well known. Here, we examined the possibility that a calcium channel blocker could improve cognitive function in a type 2 diabetic mouse model, KK-A^y. KK-A^y mice subjected to 20 trials of a passive avoidance task every week from 7 weeks of age exhibited impairment of the increase in avoidance rate and, moreover, exaggeration of its age-dependent decline, especially after 12 weeks of age. Oral administration of nifedipine at a nonhypotensive dose (0.001% in laboratory chow) to KK-A^y mice from 10 weeks of age improved cognitive function. Nifedipine treatment decreased serum insulin level to one fifth of that in KK-A^y mice without nifedipine. Moreover, nifedipine treatment significantly reduced superoxide anion production in the brain. Furthermore, treatment with nifedipine markedly reduced the mRNA level of Id-1, inhibitor of neural differentiation, in the brain hippocampus. We also observed the increase in blood flow in the brain in KK-A^y mice with nifedipine treatment compared with nontreated mice. Taken together, our findings suggest that nifedipine ameliorates impaired cognitive function in type 2 diabetic mice, at least because of attenuation of hyperinsulinemia and superoxide production in the brain and possible upregulation of the neural differentiation-controlling gene, Id-1.

Key Words: diabetes mellitus • cognitive impairment • calcium channel blocker • oxidative stress • neural differentiation